[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-use":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,53,0,25,[9,46,72,98,126,148,177,196,225,253,302,325,352,374,405,433,476,501,522,543,566,590,615,639,668],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643978","phase-1-cannabis-effects-on-opioid-self-administration-100643978",false,"NCT07668635","Cannabis Effects on Opioid Self-Administration","Impact of Cannabis on Opioid Self-Administration","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder who experience opioid withdrawal\n* No allergies or adverse reactions to cannabis or opioids\n* Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks\n\nExclusion Criteria:\n\n* Individuals seeking treatment for opioid use disorder","ALL","18 Years","55 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive\u002Fdesire to take opioids.",[28,29],"Opioid Use Disorder","Cannabis Use",[31,32],"opioid use","cannabis","NOT_YET_RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-20","ACTUAL",{"date":39,"type":22},"2026-09-30",{"date":41,"type":22},"2031-07-30",{"name":43,"class":44},"Shanna Babalonis, PhD","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100641909","phase-1-cannabis-and-opioid-use-disorder-study-2-100641909","NCT07661446","Cannabis and Opioid Use Disorder, Study 2","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder\n\nExclusion Criteria:\n\n* Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids",{"count":53,"type":22},100,[25],"This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.",[57,29],"Opioid Use Disorders",[59,60,61,62,63,64],"Cannabis","marijuana","opioid","opioid use disorder","opioid withdrawal","opioid interaction",{"date":36,"type":37},{"date":67,"type":22},"2026-10-01",{"date":69,"type":22},"2030-01-30",{"name":71,"class":44},"University of Kentucky",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100543105","phase-1-examining-the-role-of-tolerance-on-dose-dependent-effects-of-acute-thc-on-oculomotor-and-cognitive-performance-100543105","NCT06351540","Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance","Inclusion Criteria:\n\n* Inclusion criteria: Healthy non-treatment seeking adults (age 18 to 60, N = 40) who report\n* (a) infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline, or\n* (b) report frequent cannabis use defined as \\> 5 days per week for \\> 1 year with a positive THC urine toxicology at baseline.\n\nThese criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.\n\nExclusion Criteria:\n\n* (1) meet DSM-V criteria for substance use disorders other than tobacco, cannabis, or caffeine,\n* (2) are currently receiving or interested in immediately receiving behavioral treatment or medication for cannabis cessation,\n* (3) current use of any medications that could affect study outcomes,\n* (4) test positive for drugs of abuse (other than cannabis) and\u002For breath alcohol test at study admission,\n* (5) have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity,\n* (6) are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding,\n* (7) have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina), or (8) are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",true,"60 Years",{"count":81,"type":22},40,[25],"The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.",[29,85,86],"Impaired Driving","Cognitive Impairment",[32,88,89],"THC","impairment","2026-08-12",{"date":92,"type":37},"2026-08-14",{"date":67,"type":22},{"date":95,"type":22},"2027-07-01",{"name":97,"class":44},"Johns Hopkins University",{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":45},"100476614","cars-cannabis-and-alcohol-reduction-study-100476614","NCT05486234","CARS: Cannabis and Alcohol Reduction Study","Brief Computerized Intervention for Reducing Adolescent Cannabis and Alcohol Use","CARS","Inclusion Criteria:\n\n* between the ages of 13 and 17\n* be seeking treatment for either cannabis or alcohol use;\n* report co-occurring alcohol and cannabis use during the past three months (i.e., participants who report using both alcohol and cannabis during the three months prior to participation in the study, regardless of if the use was simultaneous)\n* have a caregiver willing to participate and provide consent.","13 Years","17 Years",{"count":109,"type":22},52,[111],"NA","The study will test a computerized treatment with subjects ages 13-17 years who are seeking treatment for alcohol and\u002For cannabis use. Follow-up assessments will be conducted at one- and three-months following treatment.",[29,114,115,116],"Alcohol Use, Unspecified","Substance Use","Substance Use Disorders","RECRUITING","2026-08-11",{"date":120,"type":37},"2026-08-13",{"date":122,"type":37},"2023-01-25",{"date":67,"type":22},{"name":125,"class":44},"Medical University of South Carolina",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":78,"sex":17,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100536060","distinguishing-alcohol-intoxication-cannabis-intoxication-and-co-intoxication-using-electroencephalography-eeg-100536060","NCT06259916","Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)","Developing Predictive Models to Distinguish Alcohol Use, Cannabis Use and Co-use: An Exploration of Electroencephalography (EEG) Metrics and Traditional Intoxication Measures","Inclusion Criteria:\n\n* 21-50 years old\n* Heavy drinkers (consuming more than 4 drinks\u002Fday or more than 14 drinks\u002Fweek for men, or more than 3 drinks\u002Fday or more than 7 drinks\u002Fweek for women)\n* Regular users of legal-market flower cannabis (at least 2x\u002Fweek in past 3 months)\n* report simultaneously using alcohol and legal-market flower cannabis at least once per month in the past 3 months\n* English speakers.\n\nExclusion Criteria:\n\n* Daily tobacco users\n* Diagnosed with or seeking treatment for alcohol use disorder (AUD) or other substance use disorder (SUD)\n* Females cannot be pregnant, breastfeeding or trying to become pregnant\n* Meet criteria for psychotic, bipolar or major depressive disorder with suicidal ideation, or history of these disorders, 5) Current use of psychotropic (except anti-depressants)\n* Report illicit drug use in past 60-days or fail drug screen on the day of the study appointment\n* Major medical condition contraindicating alcohol and\u002For cannabis consumption.","21 Years","50 Years",{"count":136,"type":22},99,[111],"This is a randomized, parallel-group study designed to explore the differences between cannabis intoxication, alcohol intoxication and co-intoxication involving both alcohol and cannabis, utilizing electroencephalography (EEG) as well as more traditional intoxication measures such as breath alcohol concentration and balance metrics. If eligible for the study, participants will be randomized to complete one study session in our mobile laboratory, during which they will use either alcohol, cannabis (which will be self-administered, ad libitum) or both alcohol and cannabis.",[29,114],"2026-08-10",{"date":118,"type":37},{"date":143,"type":37},"2024-01-05",{"date":145,"type":22},"2027-05-30",{"name":147,"class":44},"Colorado State University",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100545382","phase-1-warrior-care-cannabis-behavioral-health-100545382","NCT06381180","Warrior CARE: Cannabis Behavioral Health","Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health","CBH","Inclusion Criteria:\n\n* a healthy veteran who has served in a branch of the US armed forces\n* report using cannabis within the past year\n* currently meet DSM-5 criteria for PTSD and a score of 25 or greater on the CAPS-5 (the anchor, or index, trauma does not have to be related to military service)\n* between the ages of 19-69 years old\n* not seeking treatment for Cannabis Use Disorder\n* stable (i.e., under the care of a physician or therapist and not experiencing acute symptoms) on psychotropic medications and\u002For psychotherapy before the study begins (participants can be in treatment for PTSD)\n* agree to adhere to study procedures\n\nExclusion Criteria:\n\n* pregnant, lactating, or heterosexually active women and not using medically approved birth control\n* current or past bipolar or psychotic disorder as determined using the SCID-5\n* at immediate high risk for suicide based on the C-SSRS\n* current SUD other than Nicotine Use Disorder and Alcohol Use Disorder (mild or moderate)\n* allergies and\u002For other contradictions for using cannabis\n* any clinically significant medical problems\n* systolic\u002Fdiastolic BP \\>140\u002F90 mmHg or systolic BP \\\u003C95 mmHg\n* elevated liver function tests\n* exhibit cognitive impairment (\\\u003C80 IQ)\n* enrolled in another clinical trial or have received any drug as part of a research study within 30 days of dosing\n* used a prescription medication (with the exception of birth control) within 14 days of study entry that in the opinion of the medically responsible investigator will interfere with the safety of the participant or the study results\n* unable to provide informed consent","19 Years","69 Years",{"count":159,"type":22},500,[25,161],"PHASE2","This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.",[164,29,165,166,167],"Post Traumatic Stress Disorder","Suicide","Veterans","Marijuana","2026-08-04",{"date":170,"type":37},"2026-08-07",{"date":172,"type":37},"2025-09-22",{"date":174,"type":22},"2030-12-31",{"name":176,"class":44},"Wayne State University",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":45},"100472469","phase-1-behavioral-pharmacology-of-thc-and-beta-myrcene-100472469","NCT05432284","Behavioral Pharmacology of THC and Beta-Myrcene","Inclusion Criteria:\n\n1. Have provided written informed consent\n2. Be between the ages of 18 and 55\n3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission\n5. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.\n6. Have a body mass index (BMI) in the range of 18 to 36 kg\u002Fm2\n7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg\n8. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene).\n9. Demonstrate competency on cognitive performance measures at screening visit (e.g., PASAT score over 75).\n\nExclusion Criteria:\n\n1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;\n2. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.\n3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.\n4. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.\n5. Cannabis use that is inconsistent with protocol requirements.\n6. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).\n7. Individuals with anemia or who have donated blood in the prior 30 days",{"count":184,"type":22},32,[25],"This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.",[29],"2026-07-30",{"date":190,"type":37},"2026-07-31",{"date":192,"type":22},"2027-07",{"date":194,"type":22},"2028-11",{"name":97,"class":44},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":221,"leadSponsor":223,"locationsCount":45},"100649077","veaet-h-for-chronic-pain-patients-using-medical-cannabis-in-israel---a-feasibility-study-100649077","NCT07732062","vEAET-H for Chronic Pain Patients Using Medical Cannabis in Israel - A Feasibility Study","A Group-Based, Virtual Emotional Awareness and Expression Therapy Intervention - Hebrew (EAET-H) for Chronic Pain Patients Treated With Medical Cannabis in Israel - A Feasibility Study","vEAET-H","Inclusion Criteria:\n\n1. Diagnosed with any chronic musculoskeletal pain (≥ three months in duration) including back, neck, limb or pelvic pain, tension headache and fibromyalgia;\n2. Treated with medical Cannabis;\n3. Physical and mental ability to participate in group discussions;\n4. Fluent in reading and speaking Hebrew.\n\nExclusion Criteria:\n\n1. Chronic pain conditions not classified as chronic primary pain. These include neuropathies such as carpal or tarsal tunnel syndrome, radiculopathy, and neuralgia;\n2. Primary headache disorders such as cluster headaches;\n3. Cancer-related pain;\n4. Burn- or infection-related chronic pain;\n5. Autoimmune diseases typically associated with pain, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, and sickle cell disease;\n6. Inflammatory systemic diseases causing pain, including osteoarthritis or gout.\n7. Severe mental illness or psychiatric disorder such as schizophrenia, bipolar I disorder, multiple personality disorder, or dissociative identity disorder not controlled with medications, active suicide or violence risk in the past year, active severe alcohol or substance use disorder, self-reported use of intravenous drugs.\n8. Participant with a significant negative life event within the past six months, such as the death of a close person, significant loss of income, or another traumatic or highly stressful event, which may substantially affect the participant's emotional state, safety, or ability to participate in the intervention;\n9. Current participation in another psychological or behavioral therapy, program, or clinical study.",{"count":205,"type":22},42,[111],"The goal of this clinical trial is to evaluate whether a culturally adapted, virtual, group-based emotional therapy called Emotional Awareness and Expression Therapy is feasible and whether it can help reduce chronic pain and improve emotional well-being among Israeli adults who suffer from chronic musculoskeletal pain and are treated with medical cannabis.\n\nParticipants will attend a weekly 1.5-hour virtual group therapy session for 8 weeks, except for the first session, which will be held in-person at the hospital's clinic. The participants will take part in group discussions and emotional processing exercises, complete questionnaires about pain levels, mood, sleep, and quality of life, and continue their usual medical treatment as prescribed by their doctors.",[209,29],"Chronic Musculoskeletal Pain",[211,29,212,213,214,215,216],"Chronic musculoskeletal pain","Emotional Awareness and Expression Therapy","Emotional Therapy","Psychological Therapy","Group-Based","telehealth","2026-07-27",{"date":219,"type":37},"2026-07-28",{"date":67,"type":22},{"date":222,"type":22},"2027-10-01",{"name":224,"class":44},"Reuth Rehabilitation Hospital",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":45},"100645458","testing-warning-labels-for-retail-cannabis-products-using-a-discrete-choice-experiment-100645458","NCT07701304","Testing Warning Labels for Retail Cannabis Products Using a Discrete Choice Experiment","Developing and Testing Warning Labels for Retail Cannabis Products","Eligibility for participation includes: 1) being 21 years of age or older, 2) being able to speak and understand English, 3) self-reported having consumed cannabis in the last 30 days (any mode, e.g., flower, vape, edible, etc.), and 4) residing in a U.S. state or jurisdiction where retail (i.e., non-medical) cannabis use is legal.",{"count":233,"type":22},450,[111],"This discrete choice experiment (DCE) study aims to address gaps in cannabis packaging regulatory research by testing how variations in cannabis packaging and health warning design impact reactions to packaging and intentions about cannabis use. The goal of this work is to identify the most effective combination of health warning features to improve consumer awareness of cannabis health risks. Establishing criteria for cannabis products in the US is critical because inconsistent state guidelines have resulted in contradictory policies in legal retail states, arguably leading to increased hazardous use and failure to meet public health standards. The contributions of this study's outcomes are expected to be significant because they will benefit public health as cannabis becomes available in legal retail markets and regulatory and governmental agencies seek effective ways to communicate cannabis risks to the public.",[29,237,238],"Risk Perception","Decision Making",[240,241,242,243,244],"Cannabis warning labels","Discrete choice experiment","Risk perception","Cannabis use","Health communication","2026-07-24",{"date":217,"type":37},{"date":248,"type":37},"2026-05-19",{"date":250,"type":22},"2026-12-31",{"name":252,"class":44},"University of Oklahoma",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":78,"sex":17,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":271,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100648636","clinician-practice-companion-to-address-youth-substance-use-100648636","NCT07725289","Clinician Practice Companion to Address Youth Substance Use","Inclusion Criteria:\n\n* Ages 14 to 24 years.\n* Uses drugs or alcohol (past year).\n* Receiving care at a participating study site.\n\nExclusion Criteria:\n\n* Cognitive limitations or intellectual disabilities that prevent provision of informed consent.\n* Any medical or psychiatric condition causing acute distress or requiring emergency evaluation.\n* Current membership on a study Community Advisory Board.","14 Years","24 Years",{"count":262,"type":22},60,[111],"Substance use, including the use of opioids, cannabis, and other drugs, is common among adolescents and young adults, and overdose has become a leading cause of death among youth in Canada and the United States. Many young people who use substances also experience co-occurring mental health concerns. Evidence-based approaches to youth substance use care exist, including harm reduction, overdose prevention (such as naloxone and take-home drug testing strips), and medications for addiction treatment. These approaches remain adult-oriented, however, unevenly implemented in youth-serving settings, and insufficiently centered on the needs and goals of youth and their families.\n\nThis study develops and pilot tests a written \"practice companion\" that helps clinicians and other trusted adults provide developmentally appropriate substance use care to youth ages 14 to 24 in hospital and community settings. The practice companion offers practical, easy-to-use guidance organized by substance and by pattern of use. It addresses cannabis and other substances that youth commonly use and that clinicians frequently seek support with, alongside a strong focus on overdose prevention through its core elements: naloxone, take-home drug testing strips, harm reduction education, and medications for opioid use disorder. It also attends to co-occurring mental health needs and to how gender, sexuality, housing instability, and other social and structural contexts shape substance use and care.\n\nThe research team will first interview youth who use substances, their families and caregivers, and clinicians to learn how each element of care should be adapted for young people. The team will then produce the practice companion and pilot test it with 60 youth across three sites, in British Columbia, Québec, and Massachusetts. After receiving care guided by the practice companion, youth will complete an interview about whether the care was relevant, useful, appropriate, and acceptable. Families and clinicians will also be interviewed to assess how feasible, sustainable, and faithful to its design the practice companion is in practice.\n\nThroughout the study, the team will work closely with youth and families who have lived experience through a community-based participatory research approach that includes Community Advisory Boards. The work centers equity for Black, Indigenous, and other racialized youth, Two-Spirit and LGBTQ+ youth, and youth experiencing housing instability. Findings will guide a larger future study of the practice companion's effectiveness.",[115,266,267,29,28,268,269,270],"Substance-Related Disorders","Adolescent Substance Use","Drug Overdose","Overdose Prevention","Co-occurring Mental Health Conditions",[272,273,274,275,276,59,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292],"Adolescents","Young adults","Youth","Substance use","Substance use care","Naloxone","Harm reduction","Take-home drug testing strips","Fentanyl","Medications for opioid use disorder (MOUD)","Buprenorphine","Methadone","Overdose prevention","Co-occurring mental health","Youth- and family-centred care","Patient-reported outcomes","Health equity","Implementation science","ADAPT-ITT","Community-based participatory research","Toolkit","2026-07-23",{"date":217,"type":37},{"date":296,"type":22},"2027-01",{"date":298,"type":22},"2029-12",{"name":300,"class":44},"Massachusetts General Hospital",5,{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":309,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":45},"100645590","brief-family-based-cannabis-use-intervention-for-youth-with-early-juvenile-justice-involvement-100645590","NCT07700849","Brief Family-Based Cannabis Use Intervention for Youth With Early Juvenile Justice Involvement","JJ-CAPE","Inclusion Criteria: 1) parent and youth are English or Spanish speaking, 2) legal guardian is able to consent for their own and juvenile's participation, 3) youth flags for CU on either the Drug\u002FAlcohol scale of the MAYSI-2 or on the CRAFFT 2.0, 4) not currently in substance use treatment elsewhere, and 5) youth currently residing in the community.\n\nExclusion Criteria: Youth and parents will not be able to participate in the present study if they have developmental or cognitive delays or a major psychiatric disorder, documented in the intake materials, that would interfere with completing consent, assessments, or the intervention","12 Years","16 Years",{"count":262,"type":22},[111],"The goal of this randomized clinical trial is to learn if a brief family-based intervention in effective in reducing cannabis use and delinquency in youth participating in juvenile diversion. The main questions it aims to answer are:\n\nHypothesis 1: the intervention will be (a) feasible, as evidenced by enrollment rates (\\> 80%), follow-up rates (\\> 80%), and withdrawal rates (\\\u003C 20%); and (b) acceptable, as evidenced by \\> 80% of treatment evaluation ratings in the highest two Likert rating categories and positive exit interview feedback.\n\nHypothesis 2: those parents in the experimental condition, as compared to the active comparison psychoeducation condition, will evidence greater improvement over time in the hypothesized family-level mechanisms proposed in the intervention (i.e., parenting practices and parent well-being) as well as in youth-level outcomes, including cannabis use, recidivism, and HIV\u002FSTI risk.\n\nResearchers will compare the family-based treatment to parenting psychoeducation. Caregiver and youth participants will complete measures relevant to primary outcomes and putative mechanisms at baseline, 3-month, and 6-month follow-ups.",[29,315],"Delinquency","2026-07-07",{"date":318,"type":37},"2026-07-14",{"date":320,"type":22},"2026-07-15",{"date":322,"type":22},"2029-02-28",{"name":324,"class":44},"Rhode Island Hospital",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":45},"100646059","early-phase-1-lung-health-and-breath-biomarkers-acute-effects-of-inhaled-cannabis-100646059","NCT07694466","Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis","Lung Health and Breath Biomarkers: Acute Effects of Combusted and Vaporized Cannabis Inhalation Compared to Tobacco Cigarette Combustion in the Human Laboratory","Inclusion Criteria:\n\n1. English-speaking,\n2. Literate adults,\n3. Male or female,\n4. Between the ages of 18 and 55,\n5. Body Mass Index from 18.5 and 32.0 kg\u002Fm2,\n6. Able to provide written informed consent and perform all study procedures,\n7. Current recreational cannabis users - must report past 30-day cannabis use and at least 5 exposures in the past year (minimum use criteria); no limit on maximum use,\n8. Past year history of vaporized or smoked cannabis use to intoxication,\n9. Past 30-day use of combusted tobacco,\n10. Not currently seeking treatment for cannabis, tobacco cigarettes, or other drug use,\n11. If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n12. Negative urine drug test for drugs of abuse (other than cannabis) before every Laboratory Session, and\n13. Otherwise, healthy as determined by the investigator based on medical history, physical examination, vital signs, laboratory chemistries (blood chemistry with liver function tests and hematology, urinalysis, and microscopic evaluation, 12-lead electrocardiogram).\n\nExclusion Criteria:\n\n1. Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n2. Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n3. Existing or significant lung health problems that could interfere with the study,\n4. Current or history of major psychiatric disorder that would limit the participant's ability to participate in the study (e.g., bipolar disorder),\n5. Exclusive use of tobacco or cannabis through vapes and Electronic Nicotine Delivery Systems (ENDS) products,\n6. Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study (as determined by the study physician),\n7. Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n8. Clinically significant abnormal laboratory findings (e.g., liver function tests greater than 3x the upper limits of normal range),\n9. History of seizure disorder,\n10. Clinically significant history of head injuries requiring medical management or long-lasting sequelae.",{"count":333,"type":22},12,[335],"EARLY_PHASE1","This outpatient study examines how inhaled cannabis, combustible or vaporized, alters lung health and breath biomarkers compared to a tobacco cigarette.",[29,338,339],"Tobacco","Biomarkers",[341,32,342],"vaping","tobacco","2026-07-06",{"date":345,"type":37},"2026-07-10",{"date":347,"type":22},"2026-09-01",{"date":349,"type":22},"2027-06-01",{"name":351,"class":44},"Hannah Harris",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":372,"locationsCount":4},"100548538","developing-and-testing-an-online-intervention-for-alcohol-and-cannabis-misuse-and-healthy-relationship-skills-among-young-adult-couples-100548538","NCT06422299","Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Young Adult Couples","Developing and Testing an Online Intervention for Decreasing Alcohol and Cannabis Misuse and Increasing Healthy Relationship Skills Among Young Adult Couples: A Comprehensive Mixed-methods Approach","Inclusion Criteria:\n\n* Both partners in the couple are 18-29 years old\n* In a committed romantic relationship (e.g., dating seriously, cohabiting, married) with each other for at least 3 months\n* Face-to-face contact their partner at least 5 days per week\n* Live in Washington State\n* Have a valid email address and access to a cell phone\n* Report alcohol and cannabis co-use at least three times in the past month\n* Willingness to: complete online surveys during the allotted time frames, receive text messages and emails from the project, complete a baseline session, and participate during the same time period as their partner\n\nExclusion Criteria:\n\n* Couples who endorse any perpetration or receipt of severe interpersonal aggression during screening will be excluded and provided with resources","29 Years",{"count":262,"type":22},[111],"The goal of this clinical trial is to develop and test a brief online intervention to reduce alcohol and cannabis misuse and improve healthy relationship skills among young adult couples. The main questions it aims to answer are:\n\n* Will the intervention be feasible and acceptable to young adult couples?\n* Will the intervention demonstrate initial efficacy in reducing risky substance use and increasing relationship functioning?\n\nEligible couples will complete a virtual baseline session and be randomized to intervention condition (online intervention with 3-5 weeks of self-paced modules) or control condition (no intervention). Couples will complete two follow-up surveys (post-assessment - approximately 5 weeks after baseline, 3-month). Couples in the control condition will be offered the intervention after 3-month follow-up.\n\nResearchers will compare intervention and control groups to see if there there is a difference between the groups on substance misuse and relationship functioning at post-assessment and 3-month follow-up.",[364,29,365],"Alcohol Drinking","Couples",[367],"alcohol use, cannabis use, couples, healthy relationships, young adults",{"date":369,"type":37},"2026-07-08",{"date":67,"type":22},{"date":222,"type":22},{"name":373,"class":44},"University of Washington",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":382,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":390,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":45},"100630574","feasibility-and-acceptability-trial-to-reduce-tobacco-and-cannabis-use-during-pregnancy-and-postpartum-100630574","NCT07489443","Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum","Partnering With Pregnant and Postpartum People to Co-Create a Novel Intervention to Reduce Tobacco and Cannabis Use","PICTURe","Inclusion Criteria:\n\n* Confirmed pregnant\n* Under 26 weeks gestation\n* Plan to remain pregnant\n* English speaking\n* Use of combustible tobacco at least once a week during pregnancy, or at least once a week in the 3 months before pregnancy if stopped\n* Use of cannabis at any frequency during pregnancy or in the 3 months before pregnancy if stopped\n\nExclusion Criteria:\n\n* Current opioid use or active treatment for Opioid Use Disorder\n* Unable to provide informed consent in English\n* Under 18 years old","FEMALE",{"count":7,"type":22},[111],"Using both tobacco and cannabis during pregnancy is more common in minoritized groups and can make quitting smoking in pregnancy and remaining smoke free postpartum difficult. Investigators will test an intervention to address prenatal depressive symptoms to encourage people to quit tobacco and cannabis during pregnancy and stay quit postpartum.",[387,29,388,389],"Perinatal","Tobacco Use","Smoking Cessation",[342,391,392,393,394,395,32,396],"perinatal","pregnancy","smoking","cessation","postpartum","intervention","2026-07-01",{"date":343,"type":37},{"date":400,"type":37},"2026-06-17",{"date":402,"type":22},"2027-10",{"name":404,"class":44},"University of Pittsburgh",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":413,"enrollmentInfo":414,"targetDuration":4,"studyType":416,"phases":4,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":45},"100584583","study-of-an-oral-fluid-testing-approach-100584583","NCT06891235","Study of an Oral Fluid Testing Approach","Oral Fluid Testing to Assess Cannabis Non-Use in Remote Clinical Trials","SOFTA","Inclusion Criteria:\n\n* Age 18 to 30 years\n* Cannabis use on \\>=1x\u002Fweek in the past 30 days\n* Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer)\n* Ability to read and speak English\n* Availability for duration of the study (3-4 weeks).\n* To proceed to oral fluid testing, positive result for urinary TCH-COOH\n\nExclusion Criteria:\n\n• Inability\u002Funwillingness to provide contact information","30 Years",{"count":415,"type":22},200,"OBSERVATIONAL","The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across \\~3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (\\~Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (\\~Day 21; TLFB interview, urine test, oral fluid test, survey, interview).",[29,419,420],"Cannabis Intoxication","Cannabis Use Disorder",[422,423,424],"cannabis use","young adult","oral fluid testing","2026-06-27",{"date":397,"type":37},{"date":428,"type":37},"2025-10-27",{"date":430,"type":22},"2027-05",{"name":432,"class":44},"Boston Children's Hospital",{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":259,"maxAge":107,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":466,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":45},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder",{"count":442,"type":22},80,[111],"This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[29,446,420,447,419,448,449,450,451,452,167,453,454,455,456,457,458,459,460,461,115,116,462,463,464,465],"Cannabis Dependence","Cannabis Abuse","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[59,167,460],"2026-06-18",{"date":469,"type":37},"2026-06-22",{"date":471,"type":37},"2026-06-15",{"date":473,"type":22},"2030-05-01",{"name":475,"class":44},"Indiana University",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":78,"sex":17,"minAge":483,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":490,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":45},"100620425","smart-talk-cannabis-awareness-and-prevention-curriculum-evaluation-100620425","NCT07357454","Smart Talk: Cannabis Awareness and Prevention Curriculum Evaluation","Evaluation of the Smart Talk: Cannabis Awareness and Prevention Curriculum","Inclusion Criteria:\n\n* Middle school and high school students receiving health education at schools participating in the study\n\nExclusion Criteria:\n\n\\-","10 Years","20 Years",{"count":486,"type":22},10800,[111],"The Stanford REACH Lab's SMART TALK: Cannabis Awareness and Prevention Toolkit is a free, online educational resource to be used by educators to increase knowledge and awareness of cannabis and reduce use among youth. The aim of this study is to investigate the extent to which the curriculum changes middle and high school students' intentions to use and actual use of cannabis.",[29],[491],"youth cannabis education health prevention","2026-06-05",{"date":494,"type":37},"2026-06-08",{"date":496,"type":22},"2026-09",{"date":498,"type":22},"2030-02",{"name":500,"class":44},"Stanford University",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":17,"minAge":507,"maxAge":133,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":45},"100643636","transcranial-magnetic-stimulation-for-adolescents-and-young-adults-with-cannabis-use-disorder-100643636","NCT07634835","Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder","Inclusion Criteria:\n\n* 15-21 years old\n* For minors, parent\u002Flegal guardian able to provide consent and child able to provide assent; for adults, ability to self-consent per MacArthur Competence Assessment Tool for Clinical Research\n* Ability to comply with study procedures\n* Treatment-seeking youth diagnosed with CUD as per the Mini-International Neuropsychiatric Interview (MINI-KID (Sheehan et al., 2010) for 15-17 years old and MINI (Sheehan et al., 1998) for 18-21 years old)\n* Cannabis use 3+ days per week (or 12+ days in the past month) as verified by Timeline Followback (TLFB) (Sobell \\& Sobell, 1996)\n* Fluent in spoken English\n\nExclusion Criteria:\n\n* Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, intracranial lesions, epilepsy or seizure disorders, or individuals with a family history of epilepsy or seizure in a first degree relative, traumatic brain injury, brain tumor, stroke, neurocardiogenic syncope, mania\u002Fbipolar disorder, implanted medical devices or metallic objects in the head, current pregnancy or not using effective contraception if capable of becoming pregnant, or any other serious medical condition or contraindication as judged by the study physician; moderate to severe heart disease, pediatric populations with risk factors for neurocardiogenic syncope (history of syncope\u002Fpresyncope related to noxious stimuli, anxiety, micturation, or posture)\n* Inability to undergo MRI.\n* Diagnosis of psychosis, cognitive disability or active suicidality. The MINI (Sheehan et al., 1998, 2010) will be used to assess current psychiatric comorbidities and the Ask Suicide-Screening Questions (ASQ) will be used to assess suicidality (Horowitz et al., 2012).\n* Primary current alcohol or substance use disorder, except for caffeine or nicotine.\n* Taking a medication with high seizurogenic potential (e.g., clomipramine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion -e.g. Wellbutrin). Participants taking psychotropic medications will be included if dose is stable for ≥4 weeks with no anticipated changes during the study period. All concurrent treatments will be monitored during the study period.\n\n  * If an individual is currently taking antibiotics that affect the central nervous system such as Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin) or Imipenem, medications that have the potential of lowering seizure threshold, participation in the study will be delayed until 5 days after the last antibiotic dose.\n  * If an individual is taking antihistamines (i.e. Benadryl\u002Fdiphenhydramine), they will be asked to refrain from using the antihistamine for at least 24 hours before the TMS session. If the participant is not able to do so, they will be excluded from the study.","15 Years",{"count":509,"type":22},50,[111],"This pilot study will investigate the potential of repetitive transcranial magnetic stimulation (rTMS) to strengthen a neural circuit critical for maintaining abstinence in adolescents and youth with cannabis use disorder (CUD).",[29,420],"2026-06-02",{"date":515,"type":37},"2026-06-09",{"date":517,"type":22},"2027-03-01",{"date":519,"type":22},"2029-03-31",{"name":521,"class":44},"University of Minnesota",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":45},"100633307","joint-effort-20--evaluation-among-general-population-100633307","NCT07524985","Joint Effort 2.0 : Evaluation Among General Population","\" Joint Effort 2.0 \" Une Application Mobile de prévention et de réduction Des méfaits: évaluation auprès de Consommateurs de Cannabis","Inclusion Criteria:\n\n* Aged 18 years old or older\n* Be an active non-medical cannabis user (ie. self reported past month usage)\n* Understand, read and write French\n* Own a smartphone (iPhone)\n\nExclusion Criteria:\n\n* None",{"count":530,"type":22},110,[111],"This study aims to evaluate a mobile app designed to promote the safe use of cannabis among adult users in Quebec.",[29],"2026-06-01",{"date":536,"type":37},"2026-06-03",{"date":538,"type":37},"2026-04-30",{"date":540,"type":22},"2027-04",{"name":542,"class":44},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":78,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":554,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":45},"100615766","phase-2-acute-effects-of-cannabis-on-cognition-and-affect-100615766","NCT07296874","Acute Effects of Cannabis on Cognition and Affect","Inclusion Criteria:\n\n* be 21 years of age or older\n* be fluent in English\n* use of cannabis at least once a week for at least one year\n* inhalation as their typical method of administration\n* be willing to abstain from cannabis on the day of their scheduled testing session\n\nExclusion Criteria:\n\n* neurological conditions (e.g., neurodegenerative disorders, severe head injury, multiple concussions)\n* serious psychiatric conditions (e.g., psychosis, bipolar disorder)\n* family history of psychosis\n* intellectual disabilities or learning disorders (e.g., dyslexia)\n* chronic medical conditions that affect cognition or increase risk of cannabis use or exposure to cold water (e.g., heart disease, diabetes, Reynaud's disease, history of frostbite, peripheral neuropathy, history of fainting or seizures, fractures or wounds on both hands or wrists),\n* heart disease\n* BMI \\> 34\n* pregnant or lactating\n* use of illicit drugs in past 6 months\n* heavy use of alcohol (drinking \\>4 drinks \\>4 times per week)\n* nicotine\u002Ftobacco use\n* have experienced a severe adverse reaction to cannabis (e.g., panic attack, psychosis)",{"count":550,"type":22},90,[161],"This study will examine how a moderate dose of THC affects mood, stress responses, and cognitive functioning in regular cannabis users. The study uses a double-blind, placebo-controlled, crossover design, meaning each participant will complete two sessions. Specifically, each participant will be given active cannabis (20 mg THC) in one session, and placebo in the other session. The order will be randomized across participants, so half will receive cannabis first, and the other half will receive placebo first.\n\nNinety adults who use cannabis at least weekly will be recruited from the local community. After an online screening survey, eligible participants will attend a laboratory visit where the participants will provide informed consent and complete saliva and urine drug tests to confirm recent abstinence from cannabis and absence of other drugs. Participants who pass screening will complete baseline questionnaires of cannabis use patterns, depression, anxiety, ADHD symptoms, emotion regulation, affect, and demographic information.\n\nCannabis and placebo materials (obtained from NIDA) will be vaporized using a Volcano vaporizer device. Participants will inhale the vapor under supervision, and neither the participant nor the researcher assessing outcomes will know which product is administered. After vaping, participants will complete repeated mood ratings, saliva samples, and a battery of cognitive tests assessing executive functions like planning, inhibition, working memory, and cognitive flexibility.\n\nParticipants will also complete a standardized stress challenge (the Maastricht Acute Stress Test), which involves repeated trials of placing their hand in cold water and doing challenging mental math, followed by additional mood ratings and saliva samples. The participants will then watch a nature video and report their feelings of awe and affect.\n\nAt the end of each session, participants will remain in a supervised room with entertainment and snacks until at least four hours have passed since vaping and the participants report feeling sober. The participants will then return for a second session with the opposite study condition (THC or placebo) one week later. Both sessions follow the same procedures. Participants are fully debriefed after completing the study.",[29],[59,88,555,556,557],"Executive functioning","Stress reactivity","Affect","2026-05-28",{"date":534,"type":37},{"date":561,"type":22},"2026-07",{"date":563,"type":22},"2028-05",{"name":565,"class":44},"Washington State University",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":78,"sex":17,"minAge":18,"maxAge":572,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":580,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":45},"100608046","precision-brain-stimulation-to-reduce-cannabis-craving-in-schizophrenia-100608046","NCT07196462","Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia","Inclusion Criteria for Psychosis Participants:\n\n* Age between 18-65 years\n* Diagnosis of a psychotic disorder according to DSM-5 criteria and confirmed by SCID\n* Current cannabis use of at least 2\u002F10 on a Visual Analog Scale\n* Current cannabis use (confirmed by urine cannabis testing)\n* Must be able to read, speak and understand English\n* Must be judged by study staff to be capable of completing the study procedures\n* Participants will be in stable outpatient psychiatric treatment and psychiatrically stable with no recent (within the past 30 days) psychiatric hospitalizations or changes in their psychiatric medication regimens.\n\nInclusion Criteria for Healthy Controls:\n\n\\- All of the above except for participants will not have a diagnosis of a psychotic disorder nor a first-degree relative with a psychotic disorder.\n\nExclusion Criteria for ALL participants:\n\n* DSM-5 intellectual disability\n* Substance use disorder (other than cannabis or nicotine) within the past three months\n* Positive urine drug screen for illicit substance use that can increase seizure risk (cocaine, benzodiazepines, amphetamine, methamphetamine)\n* Any history of a progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tuberous sclerosis, Alzheimer's Disease) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions\n* History of head trauma resulting in any loss of consciousness (\\>15 minutes) or neurological sequelae\n* Current history of poorly controlled headaches including chronic medication for migraine prevention\n* History of fainting spells of unknown or undetermined etiology that might constitute seizures\n* History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)\n* Any devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD\n* All female participants of child-bearing age will be required to have a pregnancy test; any participant who is pregnant or planning to become pregnant will not be enrolled in the study\n* Medications will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and use of CNS active drugs. The published TMS guidelines review of medications to be considered with rTMS will be taken into consideration given their described effects on cortical excitability measures.\n* Any changes in medications or hospitalizations within the past 30 days.\n* Participants who, in the investigator's opinion, might not be suitable for the study or would be unable to tolerate the study visit\n\nThese exclusion criteria strictly follow all recommended guidelines as endorsed by the International Federation of Clinical Neurophysiology and the International Society for Transcranial Stimulation.","65 Years",{"count":53,"type":22},[111],"The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder.\n\nThis is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis.\n\nAim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100).\n\nAim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100).\n\nAs an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.",[29,577,578,579],"SCHIZOPHRENIA","Psychosis","rTMS",[422,581,579,582],"schizophrenia","brain stimulation",{"date":513,"type":37},{"date":585,"type":37},"2026-01-15",{"date":587,"type":22},"2027-12-31",{"name":589,"class":44},"Vanderbilt University Medical Center",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":78,"sex":17,"minAge":310,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":45},"100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","80 Years",{"count":599,"type":22},134,[111],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[603,420,446,29,604,605,606,607],"Psychotic Disorders","Schizophrenia; Psychosis","Cognitive Dysfunction","Memory Impairment","Neuroimaging",{"date":609,"type":37},"2026-05-22",{"date":611,"type":37},"2022-04-21",{"date":430,"type":22},{"name":614,"class":44},"Douglas Mental Health University Institute",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":638},"100448422","environment-and-lung-cancer-100448422","NCT05119244","Environment and Lung Cancer","ECP","Inclusion Criteria:\n\n* Any patient from 18 y.o to 59 y.o treated in one of the three above-mentioned hospitals for primary lung cancer, whatever its stage, and agreeing to participate in this research.\n\nExclusion Criteria:\n\n* Patient denied participation.","59 Years",{"count":624,"type":22},150,[111],"Cannabis is the most consumed drug in the world and the French are the main consumers in Europe. The most recognized effects of cannabis on human health are of a neuro-psychic nature. The medical literature on the effects of cannabis on the lung in general, and on lung carcinogenesis in particular, is most often reassuring (Tashkin, Chest 2018; Zhang, Int J Cancer 2015; Ghasemiesfe JAMA Netw. Open. 2019), despite the fact that the concentration of carcinogens in cannabis smoke is higher than that contained in tobacco smoke (Moir, Chem. Res. Toxicol. 2008), and that cannabis smoking has been implicated in the occurrence of ENT cancers. Rather, research focuses on the therapeutic effects of cannabis, especially analgesics, and even on its possible anti-tumor virtues (Abrams, Jama Oncol. 2020). These reassuring data should, however, be viewed with a great deal of caution. On the one hand, the illegal nature of cannabis in most countries and its frequent association with tobacco consumption make studies on the subject difficult and often biased. On the other hand, the daily practice of oncologists, who observe numerous cases of advanced and rapidly progressive lung cancer occurring in young patients who are heavy users of cannabis, raises suspicion of an unrecognized role of cannabis in lung carcinogenesis.\n\nIn a preliminary multicenter study on French patients under 50 years of age operated for primary lung cancer (Betser, ERJ 2021), we demonstrated that cannabis consumption was extremely frequent, concerning 43% of patients, but mentioned in patients' medical records only in 4 out of 10 cases, while the smoking status was always noted.\n\nIn addition, by comparing people who smoke cannabis (always here associated with tobacco) to patients who only smoke tobacco or to non-smokers, we identified a different profile of lung cancers, with more poorly differentiated tumors, presenting at a more advanced stage (more T3-T4 versus T1-T2) requiring more complex surgery, and mostly located in the upper lobes of the lung.\n\nSimilar research work is currently underway at Gustave Roussy (Dr Pradere-Dr Planchard, Villejuif, France) on patients with metastatic lung cancer, with a focus on overall survival and molecular profile.",[29],[629],"Cannabis, Lung Cancer",{"date":631,"type":37},"2026-05-06",{"date":633,"type":37},"2021-10-01",{"date":635,"type":22},"2027-02-01",{"name":637,"class":44},"Centre Chirurgical Marie Lannelongue",3,{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":78,"sex":17,"minAge":259,"maxAge":484,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":667},"100588430","neural-and-psychiatric-consequences-of-cannabis-use-in-adolescents-100588430","NCT06941298","Neural and Psychiatric Consequences of Cannabis Use in Adolescents","Cann-Teen","Inclusion criteria at baseline.\n\n* Cannabis users: To capture a wide range of cannabis use frequency, meeting DSM-5 criteria for cannabis use disorder will not be required. However, in order to ensure sufficient exposure, we will require majority of adolescents with cannabis use to have a significant cannabis use (self-reported use on more or equal to 10 of the prior 30 days and positive THC urine toxicology).\n* Depression: Similarly, to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of \\>=30 on the Children's Depression Rating Scale-Revised (CDRS-R, for ages 14-17) and as a raw severity score of \\>=12 on the Montgomery Asberg Depression Rating Scale (MADRS, for ages 18-20). However, we plan for at least 50% of participants with depressive symptoms to have a raw severity score of \\>=40 on the CDRS-R and of \\>=20 MADRS, which are considered reliable for depression. Additionally, we will allow participants with a research diagnosis of Major Depressive Disorder as defined by the MINI, even with a CDRS-R score below 30 or a MADRS score below 12. Moreover, because there could be individuals without MDD who have current depressive symptoms, individuals who lack a diagnosis of a depressive disorder but have a CDRS-R score of 30 (or higher) or a MADRS score of 12 (or higher) will be allowed. Through careful recruitment, we will ensure distributions of depression severity. Based on our prior studies employing similar criteria, we anticipate that anhedonia, anxiety and depression severity scores will be normally distributed in our samples.\n\nExclusion criteria.\n\nAll participants:\n\n* Psychotropic medication free for more than 1 month (or more than three months for medications with a long half-life such as fluoxetine) prior to study enrollment. We have successfully enrolled hundreds of psychotropic medication-free depressed adolescents and young adults to date. Psychotherapy will be allowed.\n* MRI contraindications such as claustrophobia, metallic ink tattoos, orthodontic braces, or pacemakers\n* Positive pregnancy tests\n* Neurological illnesses and medical conditions such as unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis)\n* Estimated full-scale IQ \\\u003C=80 to ensure that participants have the ability to understand the study\n* Current SUD other than cannabis or nicotine. Excluding nicotine use will limit generalization of our findings and impact feasibility. Similarly, alcohol use will be allowed as long as it is not hazardous and does not meet criteria of a DSM-5 disorder (AUDIT-C \\>5). Therefore, nicotine and alcohol use will be allowed and controlled for. Alcohol and cannabis use (assessed based on breathalyzer from alcohol and self-report for cannabis\u002FTHC) on the day of the scan will result in rescheduling the scan as it can affect MRI data.\n* Certified for or self-reported medical cannabis use, or intent to become certified, current stimulant use (methamphetamine or cocaine) by self-report or urine toxicology. Adderall and Vyvanse for ADHD will be allowed as long as use is temporarily paused medication usage at least 3 days before neuroimaging visit. If medication is not discontinued on scan day, scanning at that time will be up to PI discretion.\n* Oral contraceptives will be allowed and controlled for in order to maximize recruitment of older adolescents.\n\nDepressed THC non-users:\n\n* DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. However, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD) are not uncommon among depressed individuals and will be allowed as long as depressive symptoms are primary. Our focus on behavioral constructs aims to address comorbidity and mechanistic overlap among psychiatric disorders. Were these diagnoses exclusionary, the sample would be highly atypical of depression.\n* Self-injurious acts (e.g. cutting) and suicidal ideations (SI) without a specific plan (defined as passive SI) are common in adolescent depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the adolescent will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission (see Protection of Human Subjects).\n\nHealthy controls will have no lifetime history of any major psychiatric diagnoses and no use of any THC.",{"count":647,"type":22},280,[111],"The goal of this study is to investigate the effects of cannabis on brain function among adolescents with depression.",[29,651],"Depression",[272,607,653,654,655,656,657],"Functional Magnetic Resonance Imaging (fMRI)","Reward","Reward Flanker Task","Reward Predication Error Task","Pain","2026-04-20",{"date":660,"type":37},"2026-04-22",{"date":662,"type":37},"2025-03-04",{"date":664,"type":22},"2029-06-01",{"name":666,"class":44},"University of Miami",2,{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":78,"sex":17,"minAge":133,"maxAge":19,"enrollmentInfo":674,"targetDuration":4,"studyType":23,"phases":675,"briefSummary":676,"conditions":677,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":684,"locationsCount":45},"100485559","phase-1-the-impact-of-product-formulation-on-the-pharmacokinetics-and-pharmacodynamics-of-cannabis-edibles-100485559","NCT05602649","The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles","Inclusion Criteria\n\n* Have provided written informed consent.\n* Be between the ages of 21 and 55.\n* Be in good general health based on screening procedures (e.g., physical exam, medical history interview, vital signs, routine blood tests).\n* Test negative for illicit drugs (including cannabis) and test negative for alcohol (0% BAC) at screening and before any study sessions.\n* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at admission for each session.\n* Have prior experience using THC-dominant cannabis.\n* Have a body mass index (BMI) in the range of 16 to 38 kg\u002Fm2.\n* Have not donated blood in the past 30 days.\n\nExclusion Criteria\n\n* Self-reported use of illicit drugs (e.g., amphetamine, cannabis, cocaine, methamphetamine, MDMA, LSD, ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.\n* History of significant allergic reaction or significant hypersensitivity to cannabis or to any of the other ingredients in the study products.\n* Current concomitant medication use that may interact with the study drug including inhibitors and inducers of CYP2CP and CYP3A4 as well as highly-protein bound drugs and drugs with a narrow therapeutic index such as warfarin, cyclosporine, and amphotericin B.\n* History of or current evidence of a significant medical condition that, in the opinion of the investigator or medical staff, will impact the participant's safety or interfere with study outcomes.\n* Evidence of current psychiatric condition (based on MINI for DSM-5).\n* Been in treatment previously for cannabis use disorder.\n* Receiving of any drug as part of a research study within the past 30 days.\n* History of epilepsy or other serious medical condition.",{"count":442,"type":22},[25],"This study will examine the pharmacokinetics and pharmacodynamics of delta-9-tetrahydrocannabinol (THC)-infused chocolates, gummies, and drinks. Healthy adults (N=40) will complete 9 drug administration sessions, including an overnight stay prior to each session. Participants will consume THC containing products in a fasted state; following drug administration, the participants will complete cognitive and psychomotor tasks, subjective assessments, have blood collected, and vital signs monitored.",[29],"2026-04-09",{"date":680,"type":37},"2026-04-13",{"date":682,"type":37},"2024-07-10",{"date":296,"type":22},{"name":97,"class":44}]